Blood Test to Detect Heart Inflammation in Sarcoidosis
Tests a blood marker from heart cells to detect heart inflammation in adults with sarcoidosis.
Key facts
- Who runs it
- Nabeel Hamzeh
- Where
- Iowa City, United StatesSee the site
- Trial code
- Registry title
- Cell Free DNA in Cardiac Sarcoidosis
- Status
- Recruiting
- People taking part
- 120 people, planned
- Started
- 1 May 2019
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- cell free DNA
- Record updated
- 9 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with sarcoidosis (with or without active heart inflammation), adults having an acute heart attack (STEMI), and healthy volunteers. Blood is tested for heart cell DNA.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Sarcoidosis, either with no sign of active heart inflammation (myocarditis) or with active myocarditis shown on a recent heart MRI or heart FDG-PET scan. Or an acute heart attack with ST elevation (STEMI): 1mm ST elevation in 2 or more neighbouring leads, symptoms started within 12 hours, and a heart procedure planned.
- Earlier treatment
- People with sarcoidosis without active myocarditis must have had no immunosuppressive therapy for at least one year. People with active myocarditis cannot be on immunosuppressive therapy.
Main reasons for not taking part
- Active smoker
- Known heart disease (other than sarcoidosis, in the sarcoidosis groups)
- Currently on immunosuppressive therapy (sarcoidosis groups)
- Unstable blood circulation (heart attack group)
- Known heart disease, high blood pressure or diabetes (healthy volunteers)
The registry criteria, word for word
Show all 4 criteriaShow less
Other criteria
- Sarcoidosis patients without evidence of active myocarditis:; Inclusion:; Diagnosis of sarcoidosis based on the ATS/ERS criteria; Normal 12 lead ECG within the past one year; Non-smoker; No immunosuppressive therapy for at least one year; Exclusion:; Known cardiac disease; Active smoker; On immunosuppressive therapy
- Sarcoidosis patients with evidence of active myocarditis:; Inclusion:; Diagnosis of sarcoidosis based on the ATS/ERS criteria; Evidence of active myocarditis based on recent cMRI or cFDG-PET; Non-smoker; Exclusion:; Known cardiac disease other than sarcoidosis; Active smoker; On immunosuppressive therapy
- Acute ST elevation myocardial infarction (STEMI):; Inclusion:; Diagnosis STEMI based on 1mm ST elevation in 2 or more contiguous leads; Symptom onset within 12 hours; Undergoing cardiac intervention for acute coronary syndrome; Able to consent for blood draw; Exclusion:; Active smoker; Hemodynamically unstable
- Healthy controls:; Inclusion:; No known cardiac disease; No known cardiovascular risk factors: hypertension, diabetes; Non-smoker
Where in United States
- University of IowaIowa City, United StatesContact: Brenda Werner, RNNot yet recruiting
About the trial
What the trial wants to find out
Sarcoidosis is a multisystem granulomatous disease of unknown cause that can affect any organ in the body, including the heart. Granulomatous myocarditis can lead to ventricular dysfunction and ventricular arrhythmias causing significant morbidity and mortality. Immunosuppressive therapy (IST) has been shown to reverse active myocarditis and preserve left ventricular (LV) function and in some cases improve LV function. In addition, IST can suppress arrhythmias that develop due to active myocarditis and prevent the formation of scar.
Read full original descriptionShow less
The potential role of cardiac biomarkers, including brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), and cardiac troponins, in detecting active myocarditis is limited and studies have been disappointing. At present, there are no biomarkers to detect active myocarditis and the use of advanced imaging modalities (FDG-PET) for assessing and monitoring active myocarditis is not feasible or practical and is associate with high radiation exposure. As such, a biomarker that is reflective of active myocarditis and that is cardiac specific will assist physicians in assessing the presence of active myocarditis to guide therapeutic decisions and to assess response to therapy which can limit further cardiac damage.
Cell free DNA (cfDNA) are fragments of genomic DNA that are released into the circulation from dying or damaged cells. It is a powerful diagnostic tool in cancer, transplant rejection and fetal medicine especially when the genomic source differs from the host. A novel technique that relies on tissue unique CpG methylation patterns can identify the tissue source of cell free DNA in an individual reflecting potential tissue injury. We will be conducting a pilot study to explore the utility of this diagnostic tool to identify granulomatous myocarditis in patients with sarcoidosis.
The 4 groups in the trial
- Sarcoidosis patients without evidence of active myocarditisExisting treatment, for comparison
A single blood draw.
Treatment: cell free DNA
- Sarcoidosis patients with evidence of active myocarditisTreatment being tested
Two blood draws 2 months apart.
Treatment: cell free DNA
- Acute ST elevation myocardial infarction (STEMI)Existing treatment, for comparison
Three blood draws, baseline, 6 hours and 24 hours.
Treatment: cell free DNA
- Healthy controlsPlacebo, for comparison
A single blood draw
Treatment: cell free DNA
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Cardiomyocyte Specific Cell Free DNA as a Marker of Cardiac Sarcoidosis
- Plain-language title
- Blood Test to Detect Heart Inflammation in SarcoidosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 January 2026